# Pharmacotherapy Rounds University of Maryland Goals, Objectives, Format, and Evaluation Criteria

#### Goal:

The goal of Pharmacotherapy Rounds is to enhance the participant's knowledge regarding the use of drug therapy to treat and/or prevent disease, of an innovative pharmacy service or a "hot topic" in health-system or community pharmacy. Participants will learn to evaluate the scientific literature and discuss its applicability to practice. Participants will learn to present complex concepts and scientific data in a clear and concise manner.

#### Format:

Dates and times will be announced via e-mail and on the University of Maryland (UM) Residency and Fellowship website). Presentations will be delivered in-person, via webinar or a combination of both.

The audience will consist of pharmacy residents, fellows, faculty, preceptors, pharmacy practitioners, pharmacy students, and invited guests. Presentations will be formal in nature and audience members will refrain from asking questions during the presentation (except to ask brief points of clarification).

The presentation must comprehensively review recent changes/new developments in the treatment of a medical disorder, describe an innovative pharmacy service, examine a pharmacotherapeutic problem in a specific patient population or address a "hot topic" in pharmacy

Individual presentations will vary in length, from 30-50 minutes in duration, and the presenter must use audiovisual aids (i.e. slides) during the presentation. The use of videos is not permitted; plug-ins cannot be added to PowerPoint presentations. Use of technologies outside of PowerPoint (e.g., Poll Everywhere) must be discussed with <a href="mailto:umresfelprogram@rx.umaryland.edu">umresfelprogram@rx.umaryland.edu</a> at least 5 business days before the presentation.

Non-UM PGY1 residents will deliver a 30-minute in-person presentation while the UM PGY1 residents will present a 50-minute in-person presentation with content also delivered synchronously via webinar to those at a distance from the UM Baltimore campus. PGY-2/3 program directors will work with UM residency and fellowship administration to determine the length and format (live vs. webinar) of each of their trainee's presentation. All PGY-2/3 residents and fellows will present a 30-minute presentation in-person.

In an effort to "go green", residents and fellows will not print copies of their slides and any handouts for the presentation. PDF files of these handouts will be distributed via email to those included on the Pharmacotherapy Rounds distribution list. Those attending the presentation can print copies of the slides and handouts if they choose to do so.

# **Evaluation:**

All members of the audience will evaluate the presentation using an online standardized evaluation tool (see below) that is emailed to program attendees (usually within 24 hours of the presentation). In addition, a content expert in the field and either the program director/teaching certificate

mentor (as appropriate) must deem that the resident/fellow has met minimal passing criteria for the presentation. Minimal passing criteria is defined as achieving a score of "meets expectations" or better for terminal performance objectives 1-7 and being scored as "yes" for items 8-15.

If one or both of the evaluators deem that the presentation did not meet minimal passing criteria, a remedial plan must be developed by the program director to meet program specific requirements. Program evaluations will be used to assist in making this determination and in providing feedback to the resident/fellow. The content expert will be selected in consultation with each program director before the topic is submitted.

A program evaluation summary will be sent to the designated formal evaluators following the presentation. Prior to the presentation date, the resident or fellow will set a date and time to meet with their evaluators. The time of this meeting should be set for the week following the presentation in order to allow for the program summary evaluations to be sent to the trainee, their evaluator(s) and program director. The program summary evaluation is sent directly to the program director, and he/she will review the document to ensure that there is no negative (nonconstructive) feedback prior to distributing to the trainee and their evaluator(s).

The resident/fellow will complete the Pharmacotherapy Rounds self-evaluation form following their Pharmacotherapy Rounds presentation. This document is posted on the Pharmacotherapy Rounds website. The resident/fellow will discuss their self-evaluation with their Pharmacotherapy Rounds evaluators and maintain a copy of this in their binder. Copies of the self-evaluation are not submitted to the UM Residency and Fellowship program or Continuing Education (CE) office.

# **Preparation:**

Residents and fellows are encouraged to work with content experts/mentors when preparing their presentations. Residents and fellows are required to submit their title and learning objectives to their content experts/mentors for review before submitting to the CE office. To avoid possible duplication subject resident/fellow of matter/topics, the is required to e-mail umresfelprogram@rx.umaryland.edu with the potential topic or presentation title at least 55 business days in advance. Specific deadline dates can be found on the Pharmacotherapy Rounds schedule. Topics from the previous two years cannot be duplicated (please see website for list of previous topics). To avoid commercial bias, please do not use proprietary or trade names in the title of your presentation.

Mentors should also be consulted on developing the handout and slides for the session, writing learning objectives for CE credit, and formulating active learning questions. Each presentation will include an active learning component constructed of a case-based scenario with multiple choice questions. The active learning component should include audience polling to facilitate assessment of audience learning and feedback to audience. The active learning component should be in line with the learning objectives.

Topics that are clinical in nature will also be evaluated using the following global objective (presenters MUST still write their own topic specific objectives). Presenters will also submit a brief (2-3 sentences) educational needs assessment for the topic.

- 1. Describe the scope of the clinical issue discussed, including risk factors, pathogenesis, and existing therapies.
- 2. Evaluate the literature in support of a novel or controversial pharmacotherapeutic approach for the clinical issue.

3. Given a case description of a patient affected by the clinical issue, develop an evidence-based treatment plan.

All presentations will be offered for CE credit. A Pharmacotherapy Rounds CE Application must be completed and submitted online at least 45 business days prior to the presentation. As part of the PT Rounds CE Application, each resident/fellow must submit a copy of his/her current, up-to-date curriculum vitae. (See directions for submitting CE application– attached). You will also need to submit the name and email address of the program director and presentation evaluator(s) as part of the application. This information will be used as discussed above when sending the program evaluation summary.

\*Please note: if paperwork is not received by the due date, CE credit will NOT be offered for Pharmacotherapy Rounds.\*

# **Attendance Requirements:**

In order to obtain CE credit for the session, each audience member must complete an online evaluation and sign the attendance sheet.

University of Maryland pharmacy residents and fellows are expected to attend, at a minimum, 15 hours during their residency year; fellows and two-year residents are expected to attend 25 hours during their training program. Each resident/fellow is required to give one presentation during each training year. UM residents and fellows must sign the attendance sheet in order to be credited with attendance towards their program requirement.

All other residents should check with their respective programs for attendance expectations.

# **Additional Information:**

**Continuing Education:** Office of Continuing Education

University of Maryland School of Pharmacy

20 North Pine Street (Pharmacy Hall) - Room N309-J

Baltimore, MD 21201

continuinged@rx.umaryland.edu

Office (410) 706-0761 Fax (410) 706-4012

**Reference Citations:** Please follow the Uniform Requirements for Submitting Manuscripts to Biomedical Journals. See NEJM 1997; 336: 309-15 available on-line at: <a href="http://www.nejm.org/doi/full/10.1056/NEJM199701233360422">http://www.nejm.org/doi/full/10.1056/NEJM199701233360422</a>

# **Terminal Performance Objectives:**

Given a presentation date, an audience, and audiovisual equipment, the pharmacy resident/fellow should be able to deliver the presentation comprehensively reviewing recent changes/new developments in the treatment of a medical disorder, describing an innovative pharmacy service, examining a pharmacotherapeutic problem in a specific patient population or addressing a "hot topic" in pharmacy.

# TERMINAL PERFORMACE OBJECTIVES

Please use the following scale to rate terminal performance objectives 1-7:

**Exceeds expectations** = objective met completely, no further refinement necessary

**Meets expectations =** minor changes needed to meet objective, but appropriate for the trainee's current level of learning (i.e. PGY-1, PGY-2, or fellow)

**Below expectations =** significant changes needed to meet objective, performance level not appropriate for the trainee's current level of learning (i.e. PGY-1, PGY-2, or fellow)

- 1. Orally present information in an effective manner by speaking clearly and explaining concepts using appropriate terminology.
- 2. Deliver information in well-organized manner (sequence is logical and easy to follow, transition effectively from one concept to another).
- 3. The presenter produced well-written and aesthetically pleasing handouts and/or slides that highlighted the key points presented.
- 4. Demonstrate an in-depth knowledge of the subject matter via appropriate evaluation and interpretation of data (comprehensiveness, address key issues, include findings of major clinical trials, explain concepts completely, state the relevance and limitations of the data to the topic, explain conflicting information).
- 5. The presenter provided a summary of the key message(s) at the beginning and end of the presentation.
- 6. Formulate appropriate conclusions how this information should be used in clinical practice.
- 7. Answer questions effectively by clarifying the nature of the question (if needed), formulating an appropriate conclusion, and providing supporting evidence/data.

Please indicate if terminal performance objectives 8-15 were achieved by indicating "yes" or "no" as appropriate.

- 8. The presenter selected a topic of reasonable scope that reviews recent changes/new developments in the treatment of a medical disorder, describes an innovative pharmacy service, examines a pharmacotherapeutic problem in a specific patient population or addresses a "hot topic" in pharmacy.
- 9. The program effectively addressed each of the following learning objectives. {List the learning objectives here}.
- 10. The learning assessment activities included in this program were appropriate for the stated objectives.
- 11. The presenter referred learner to additional educational materials that will enhance understanding of content and foster application to pharmacy practice.
- 12. The presenter effectively incorporated active learning techniques.
- 13. The presenter used appropriate gestures/non-verbal communication.

- 14. The presenter referenced all sources (handout / slides / tables) following the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." (NEJM 1997; 336: 309-15.)
- 15. The program was free of all apparent bias or commercialism.

If you feel this activity was presented with bias please explain (free text).

Presentation attendees will also be provided with free text space to provide feedback on the "strengths" and "areas for improvement" for the presenter.

# Pharmacotherapy Rounds Check List (Presentations Held at the University of Maryland)

<u>AT</u>	LEAST 55 business days prior to your presentation date (please check online schedule for
exa	act due date):
	Proposed presentation topic or title should be emailed to <a href="mailto:umresfelprogram@rx.umaryland.edu">umresfelprogram@rx.umaryland.edu</a> ;
	do not use proprietary or trade names in the title of your presentation
<u>AT</u>	LEAST 45 business days prior to your presentation date (please check online schedule for
exa	act due date):
	Complete Pharmacotherapy Rounds online application including:  Be certain to check the box "I am a resident/fellow proposing a PT Rounds session" when submitting the application. This is above where you fill in the speaker information.  a. Your Name and Credentials and Title b. Your current, up-to-date Curriculum Vitae c. Disclosure Form d. Your Residency or Fellowship Director's Name and Email Address e. Your Evaluator's Name and Email Address f. Additional Evaluator's Name and Email Address (if applicable) g. Program Title: Insert appropriate title based on topic to be presented (Note – you should NOT use the brand name of a product in your title) h. Program Date i. Program Outline j. Program Focus: select from drop down box k. Designator Code: select from drop down box l. How do you plan to announce this program? Select "internal email" m. At least 3 Learning Objectives n. Educational needs assessment
	E WEEK (5 business day) prior to your presentation (email to
	nresfelprogram@rx.umaryland.edu): Slides with learning objectives
	Handouts with cover sheet
	Bring 4 copies of the attendance log to the presentation. The template for the attendance log is available on the Pharmacotherapy Rounds website. All sections of the attendance log must be completed on each sheet. The Universal Activity Number, or UAN, can be found in the appointment received for PT Rounds as well as on the online schedule.  Complete the self-evaluation form posted on the Pharmacotherapy Rounds website. This will be

discussed with your evaluators and maintained in your binder.